This study aims to compare the efficacy of apixaban and rivaroxaban in reducing clinically relevant bleeding in adults with acute venous thromboembolism (VTE).
Randomized trial design
Participants were adults diagnosed with acute VTE
Comparison of clinical bleeding rates at 3 months between apixaban and rivaroxaban
The incidence of clinically relevant bleeding was lower in the apixaban group compared to the rivaroxaban group (specific rates not provided).
No significant difference in VTE recurrence was noted between treatment groups.
Apixaban showed a better safety profile regarding bleeding complications compared to rivaroxaban.